Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826859 · ClinicalTrials.gov registry record · Phase 1
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
A Phase 1 study of Preeclampsia and Preterm Birth, sponsored by Thomas Jefferson University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 400
- Enrollment target
- 1
- Study location
NCT06826859 is a Phase 1 study of Preeclampsia and Preterm Birth that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 400 participants, below the 1,272-participant average among 39 other Preeclampsia trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06826859, a Phase 1 study of Preeclampsia and Preterm Birth, is actively recruiting participants, sponsored by Thomas Jefferson University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin pharmacology and the relationship of aspirin response and pregnancy outcome, along with a lack of consensus on aspirin dosing has limited the effective use of this intervention. The investigators aim to apply principles of clinical pharmacology to determine how to optimally utilize this low cost medication to improve maternal/child health outcomes. This is a Phase I/II randomized controlled trial of high risk pregnancies recommended aspirin; participants will be randomized to take aspirin either 162mg once daily, or 81mg twice a day. Outcomes evaluated will include the difference in aspirin response between these two dosing regimens, the individual factors that impact aspirin pharmacology in pregnancy, and evaluate markers or aspirin response that may be associated with pregnancy outcome.
Conditions Studied
Interventions
- DRUG Daily aspirin (ASA)
- DRUG Split dose aspirin (ASA)
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-06-26 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06826859
The ClinicalTrials.gov registry entry for NCT06826859 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,272-participant average among 39 other Preeclampsia trials with a reported enrollment target (69% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Preeclampsia appearing as the primary indexed condition, and to 2 interventions - of which Daily aspirin (ASA) is the first listed.
NCT06826859 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06826859 about?
NCT06826859 is a clinical study titled "Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)". Aspirin is recommended in high risk patients to reduce the risk of preeclampsia and preterm birth, which are leading causes of both maternal and neonatal morbidity and mortality, but up to 20% will have these adverse outcomes despite therapy. Gaps in knowledge regarding pregnancy specific aspirin ph...
What is the current status of trial NCT06826859?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 400 participants. The study started on 2025-06-26. Estimated completion is 2029-12-31.
What conditions does trial NCT06826859 study?
This clinical trial studies the following conditions: Preeclampsia, Preterm Birth.
What interventions are being tested in trial NCT06826859?
The interventions under investigation include: Daily aspirin (ASA) (DRUG), Split dose aspirin (ASA) (DRUG).
Who is sponsoring clinical trial NCT06826859?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826859 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pravastatin for Prevention of Preeclampsia
COMPLETED · Phase 1
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.